Ovarian Clear Cell Carcinoma

Oncology
2
Pipeline Programs
2
Companies
50
Clinical Trials
15 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
150%
Small Molecule
150%

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
NintedanibPhase 2Small Molecule1 trial
Active Trials
NCT02866370Unknown120Est. Mar 2021
GSK
GSKLONDON, United Kingdom
1 program
1
DostarlimabPhase 1/2Monoclonal Antibody5 trials
Active Trials
NCT07408063Not Yet Recruiting30Est. Jun 2030
NCT07381777Not Yet Recruiting270Est. Dec 2030
NCT06405230Recruiting40Est. Oct 2029
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab
GSKDostarlimab

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 6,979 patients across 50 trials

NCT06897527GSKDostarlimab

A Study to Evaluate the Safety of Dostarlimab in Adult Participants in India With Recurrent or Advanced Endometrial Cancer (EC)

Start: Jul 2025Est. completion: Jan 2027100 patients
Phase 4Not Yet Recruiting
NCT05855200GSKDostarlimab

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer

Start: Aug 2023Est. completion: Mar 2031892 patients
Phase 3Recruiting
NCT05201547GSKDostarlimab

Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Start: Apr 2022Est. completion: Oct 2029260 patients
Phase 3Active Not Recruiting
NCT04655976GSKDostarlimab

Efficacy Comparison of Cobolimab + Dostarlimab + Docetaxel to Dostarlimab + Docetaxel to Docetaxel Alone in Participants With Advanced Non-small Cell Lung Cancer Who Have Progressed on Prior Anti-PD-(L)1 Therapy and Chemotherapy

Start: Dec 2020Est. completion: Mar 2027758 patients
Phase 3Active Not Recruiting
NCT04679064GSKDostarlimab

Trial on NIraparib-TSR-042 (Dostarlimab) vs Physician's Choice CHEmotherapy in Recurrent, Ovarian, Fallopian Tube or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment

Start: Dec 2020Est. completion: Jan 2025427 patients
Phase 3Unknown
NCT07408063GSKDostarlimab

A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

Start: Feb 2026Est. completion: Jun 203030 patients
Phase 2Not Yet Recruiting
NCT07381777GSKDostarlimab

XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients

Start: Jan 2026Est. completion: Dec 2030270 patients
Phase 2Not Yet Recruiting
NCT07108270GSKDostarlimab

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Start: Nov 2025Est. completion: Mar 203030 patients
Phase 2Recruiting
NCT07013851GSKDostarlimab

Clinical Trial to Assess the Efficacy of Dostarlimab as Neoadjuvant Therapy in Patients With MMRd/MSI-H Stage II-III Endometrial Cancer

Start: Oct 2025Est. completion: Oct 202925 patients
Phase 2Not Yet Recruiting
NCT07115927GSKDostarlimab

pReOperative Dostarlimab and Novel Therapies in EndOmetrial Cancer

Start: Sep 2025Est. completion: Jan 203140 patients
Phase 2Not Yet Recruiting
NCT06757244GSKDostarlimab

DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer

Start: Feb 2025Est. completion: Feb 202835 patients
Phase 2Recruiting
NCT06567782GSKDostarlimab

A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Start: Feb 2025Est. completion: Oct 2028120 patients
Phase 2Recruiting
NCT06365970GSKDostarlimab

Niraparib and Dostarlimab for Patients With MMR-D/MSI-H Colorectal Cancers

Start: Jan 2025Est. completion: Jan 20280
Phase 2Withdrawn
NCT06640049GSKDostarlimab

A Study of Dostarlimab in Participants With Untreated Locally Advanced Rectal Cancer in China

Start: Oct 2024Est. completion: Apr 203123 patients
Phase 2Active Not Recruiting
NCT06278857GSKDostarlimab

SATELLITE Study (feaSibility sAfeTy Efficacy dostarLimab earLy-stage defIcient endomeTrial cancEr)

Start: Aug 2024Est. completion: Jun 202810 patients
Phase 2Recruiting
NCT06333314GSKDostarlimab

Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Start: Jul 2024Est. completion: Sep 2030120 patients
Phase 2Recruiting
NCT06317311GSKDostarlimab

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer

Start: May 2024Est. completion: Aug 202741 patients
Phase 2Active Not Recruiting
NCT06238635GSKDostarlimab

Dostarlimab and Cobolimab in Advanced Cervical Cancer

Start: Mar 2024Est. completion: Jul 202766 patients
Phase 2Active Not Recruiting
NCT06023862GSKDostarlimab

A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study)

Start: Jan 2024Est. completion: Dec 2029198 patients
Phase 2Recruiting
NCT06062420GSKDostarlimab

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Start: Nov 2023Est. completion: Jul 2027316 patients
Phase 2Active Not Recruiting
NCT05126342GSKDostarlimab

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Start: Nov 2023Est. completion: Nov 20260
Phase 2Withdrawn
NCT05855811GSKDostarlimab

PREventing Second Cancers With DOSTARlimab

Start: Jul 2023Est. completion: Mar 2029400 patients
Phase 2Recruiting
NCT05723562GSKDostarlimab

A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer

Start: Apr 2023Est. completion: Oct 2029154 patients
Phase 2Active Not Recruiting
NCT05405192GSKDostarlimab

Dostarlimab in Chemoresistant Gestational Trophoblastic Neoplasia

Start: Mar 2023Est. completion: Dec 20280
Phase 2Withdrawn
NCT05065021GSKDostarlimab

Using Genetic Profile to Determine the Treatment for Patients With Ovarian Cancer Who Previously Received a PARP-inhibitor

Start: Feb 2023Est. completion: Jun 202540 patients
Phase 2Unknown
NCT05526989GSKDostarlimab

Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma

Start: Dec 2022Est. completion: Nov 202725 patients
Phase 2Recruiting
NCT05565378GSKDostarlimab

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Start: Oct 2022Est. completion: Feb 2027351 patients
Phase 2Active Not Recruiting
NCT06926673GSKDostarlimab

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Start: Dec 2021Est. completion: May 202462 patients
Phase 2Completed
NCT04895046GSKDostarlimab

Maintenance Niraparib and Dostarlimab in Advanced Cholangiocarcinoma

Start: Oct 2021Est. completion: Sep 20230
Phase 2Withdrawn
NCT04584255GSKDostarlimab

Niraparib + Dostarlimab In BRCA Mutated Breast Cancer

Start: Dec 2020Est. completion: Jul 202962 patients
Phase 2Active Not Recruiting
NCT04581824GSKDostarlimab

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Start: Nov 2020Est. completion: Sep 2024243 patients
Phase 2Terminated
NCT04313504GSKDostarlimab

Study Evaluating the Efficacy of Niraparib and Dostarlimab (TSR-042) in Recurrent/Metastatic HNSCC

Start: Nov 2020Est. completion: Jun 202523 patients
Phase 2Active Not Recruiting
NCT04126200GSKDostarlimab

Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Start: Oct 2019Est. completion: Mar 2027208 patients
Phase 2Active Not Recruiting
NCT03654833GSKDostarlimab

Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Start: Jan 2019Est. completion: Oct 2023186 patients
Phase 2Unknown
NCT03739710GSKDostarlimab

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Start: Jan 2019Est. completion: May 2024175 patients
Phase 2Completed
NCT02866370Boehringer IngelheimNintedanib

Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium

Start: Apr 2015Est. completion: Mar 2021120 patients
Phase 2Unknown
NCT06405230GSKDostarlimab

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Start: Dec 2025Est. completion: Oct 202940 patients
Phase 1/2Recruiting
NCT06521567GSKDostarlimab

A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer

Start: Mar 2025Est. completion: Oct 202683 patients
Phase 1/2Active Not Recruiting
NCT06796907GSKDostarlimab

A Study of GSK5733584 in Combination With Anti-cancer Therapies for Advanced Solid Tumors

Start: Mar 2025Est. completion: Apr 2028392 patients
Phase 1/2Recruiting
NCT06065462GSKDostarlimab

Safety and Efficacy of Targeting PP2A in Ovarian Clear Cell Carcinoma Using Dostarlimab and LB-100

Start: Nov 2023Est. completion: Oct 202721 patients
Phase 1/2Recruiting
NCT05784012GSKDostarlimab

Two-cohort Study of Niraparib and Dostarlimab Plus (Chemo)RadIotherapy in Locally-Advanced Head and Neck Squamous Cell Carcinoma

Start: Nov 2023Est. completion: Mar 202934 patients
Phase 1/2Recruiting
NCT04926324GSKDostarlimab

A Safety Study Adding Niraparib and Dostarlimab to Radiation Therapy for Rectal Cancers

Start: Jul 2022Est. completion: Dec 20243 patients
Phase 1/2Terminated
NCT05060432GSKDostarlimab

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

Start: Sep 2021Est. completion: Jul 2025153 patients
Phase 1/2Active Not Recruiting
NCT06655818GSKDostarlimab

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM

Start: Mar 2021Est. completion: Feb 20244 patients
Phase 1/2Terminated
NCT05980416GSKDostarlimab

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Start: Aug 2023Est. completion: Jun 202588 patients
Phase 1Terminated
NCT05819892GSKDostarlimab

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

Start: Jul 2023Est. completion: Mar 202821 patients
Phase 1Recruiting
NCT05277051GSKDostarlimab

First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors

Start: Mar 2022Est. completion: Aug 2027158 patients
Phase 1Recruiting
NCT04673448GSKDostarlimab

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

Start: Oct 2021Est. completion: Sep 202618 patients
Phase 1Active Not Recruiting
NCT04544995GSKDostarlimab

Dose Escalation and Cohort Expansion Study of Niraparib and Dostarlimab in Paediatric Participants With Solid Tumors (SCOOP)

Start: Oct 2020Est. completion: Apr 202547 patients
Phase 1Terminated
NCT04446351GSKDostarlimab

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

Start: Jun 2020Est. completion: Dec 2026107 patients
Phase 1Active Not Recruiting

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
4h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
4h ago

Office Administrator

SystImmune
4h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
4h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
4h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
4h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

15 actively recruiting trials targeting 6,979 patients
Monoclonal Antibody is the dominant modality (50% of programs)
2 companies competing in this space

Related Indications

Breast Cancer(577)Prostate Cancer(385)Non-small Cell Lung Cancer(378)Multiple Myeloma(359)Cancer(249)Advanced Solid Tumors(226)Acute Myeloid Leukemia(209)Neoplasms(199)Colorectal Cancer(171)Melanoma(170)